Payment overview · 2025
General Payments
$25.10
1 reported records · 1 companies
Healthcare provider profile · identity verified
Eugene Soroka, MD
Allopathic & Osteopathic Physicians|Family Medicine · PORT HUENEME, CA · NPI 1437109683
Verified facts
What the public records show
CMS Open Payments records show Eugene Soroka, MD received $25.10 in general payments during 2025 across 1 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.10 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $25.10 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 109 |
| Gabapentin | Gabapentin | 328 | 73 |
| Metformin Hcl | Metformin Hcl | 323 | 75 |
| Lisinopril | Lisinopril | 308 | 68 |
| Furosemide | Furosemide | 238 | 59 |
| Losartan Potassium | Losartan Potassium | 220 | 62 |
| Omeprazole | Omeprazole | 205 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 47 |
| Eliquis | Apixaban | 186 | 29 |
| Glipizide | Glipizide | 182 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 170 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 35 |
| Spironolactone | Spironolactone | 150 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 44 |
| Tramadol Hcl | Tramadol Hcl | 145 | 29 |
| Famotidine | Famotidine | 134 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 39 |
| Sertraline Hcl | Sertraline Hcl | 129 | 29 |
| Xarelto | Rivaroxaban | 127 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 36 |
| Carvedilol | Carvedilol | 121 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 38 |
| Trazodone Hcl | Trazodone Hcl | 112 | 33 |
| Atenolol | Atenolol | 106 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 24 |
| Januvia | Sitagliptin Phosphate | 98 | 14 |
| Allopurinol | Allopurinol | 97 | 26 |
| Buspirone Hcl | Buspirone Hcl | 93 | 18 |
| Simvastatin | Simvastatin | 86 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 84 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 20 |
| Meloxicam | Meloxicam | 82 | 35 |
| Levetiracetam | Levetiracetam | 81 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 22 |
| Jardiance | Empagliflozin | 74 | suppressed |
| Cephalexin | Cephalexin | 72 | 43 |
| Lactulose | Lactulose | 71 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 20 |
| Azithromycin | Azithromycin | 61 | 48 |
| Potassium Chloride | Potassium Chloride | 59 | 15 |
| Ibuprofen | Ibuprofen | 57 | 25 |
| Lorazepam | Lorazepam | 57 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Permethrin | Permethrin | 56 | 30 |
| Prednisone | Prednisone | 55 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 29 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | 17 |
| Finasteride | Finasteride | 50 | 13 |
| Terazosin Hcl | Terazosin Hcl | 49 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 13 |
| Bumetanide | Bumetanide | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 18 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Mirtazapine | Mirtazapine | 37 | 18 |
| Nystatin | Nystatin | 36 | 23 |
| Valsartan | Valsartan | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | 11 |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 14 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | 11 |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tri-Vylibra Lo | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25.10 · 1 records | Lilly USA, LLC | MOUNJARO, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error